HUE027218T2 - Eljárások IGF-1 (Inzulinszerû növekedési faktor 1) hiány kezeléséhez - Google Patents

Eljárások IGF-1 (Inzulinszerû növekedési faktor 1) hiány kezeléséhez Download PDF

Info

Publication number
HUE027218T2
HUE027218T2 HUE10009976A HUE10009976A HUE027218T2 HU E027218 T2 HUE027218 T2 HU E027218T2 HU E10009976 A HUE10009976 A HU E10009976A HU E10009976 A HUE10009976 A HU E10009976A HU E027218 T2 HUE027218 T2 HU E027218T2
Authority
HU
Hungary
Prior art keywords
igf
subject
levels
normal
igfd
Prior art date
Application number
HUE10009976A
Other languages
English (en)
Inventor
Ross G Clark
Original Assignee
Ipsen Biopharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ipsen Biopharmaceuticals Inc filed Critical Ipsen Biopharmaceuticals Inc
Publication of HUE027218T2 publication Critical patent/HUE027218T2/hu

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/30—Insulin-like growth factors (Somatomedins), e.g. IGF-1, IGF-2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/575—Hormones
    • G01N2333/65—Insulin-like growth factors (Somatomedins), e.g. IGF-1, IGF-2
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/04—Endocrine or metabolic disorders

Claims (4)

  1. Szabadalmi igénypontok idnzuiirtsaérö növekedési fefeör-1ember; alany k^elésérei akí^ék pr^er in^rmi^ü nöwaksöéSf íekioM hiánya ven (SGFD), ahol azaiany a élveikéiképp van jéilehiezveí a kezelés idején vagy az iGF-t-ei történő kezdet! kezelés síéit, sRinek a magassága fepíébb 2 SD-ve! {szórás, standard de viadort} van az ugyanazon kom és nemű alany közepes afet és & kezelés idején vagy Μ IGF-1-ei törődő kezdeti kezelés előtt az IGF-1 Vérszióp feplább 1 SD-vel van az ugyanazon korú és nemű alany normái közapes szin^aiiÉ ahol az alanyra tsvé&feáaz jellemző, hogy van növekedési hormon {GH} vérszintie, a GH yérszíntje iegaíáhh normális azazőnos löt# és: nemS alany színiéhez képest, ahol az alanynak RídöS nagy affinitásé GH kötő protein vérszintje, amely legalább 2 SD-va; van normái közepes szintek alatt, ahol m alanynak nincs taron szindrómája vágy részleges növekedési hormon inszenzití vitás szindrómája; és ahol a taron szindróma páciensrevonaiköZík, aki a növekedési hormonreceptor fülkéié teljes hiányávatmndölkezik vagy teljes növekedési hormon irsszenzitivltásí szindrómát mutat feL 2Az 1. Igénypont szerinti IGF-1 felhasználás, ahol az alany felnőtt vagy gyermekgyógyászati alany
  2. 3. Az 1, vagy 2; igénypont szerinti IGF-1 felhasználás, ahol a2 IGF-1 a legalább normális iGF^t szintek eiérésérevana primer IGFO s;any korához és neméhez viszonyítva. 4>Az előző igénypontok bármelyike szerinti IGF-1 felhasználás, ahol az ?<3F~1 primer IGFD legalább egy szimptómájáí enyhíti. S. Az előző igéhypöntok bSrméiytkö szerinti IGF-1 felhasználás, ahol az alany iGFi vérszintje legalább 2,0 SD-vei az azonos körű és nemű alany normális közepes szintje alatt van.
  3. 8, AzeiyŐitg^ IGF-1 feinasználás, ahol az IGF-i 2Ö-2# Fgíks/nap dózisban von adagolva. f< Az eizö {géPpGnfök báfm^yíka szerinti IGF-i felhasználás, ahölsz IGF-i szubkutan Van adagolva. Az előző igénypontok bármelyike szerinti IGF-1 felhasználás, ahol az iGF-t egytGF-1 variáns.
  4. 8. Az elözö ígánypomok bármelyike szerint; lGF-t felhasználás, ahol az }<3f-1 egy rskombináös emberi SGF-1. 1Θ, Az előző igénypontok bármelyike szerinti IGF-1 fehesznáiás, ahol az IGF-1 egy ígf«1 variáns, amelynek hiányzik 5, vagy annál kevesebb amíoösava az N-vőgtőt, összevetve a natív löF-1-el.
HUE10009976A 2003-09-12 2004-09-09 Eljárások IGF-1 (Inzulinszerû növekedési faktor 1) hiány kezeléséhez HUE027218T2 (hu)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US50257903P 2003-09-12 2003-09-12

Publications (1)

Publication Number Publication Date
HUE027218T2 true HUE027218T2 (hu) 2016-10-28

Family

ID=34619295

Family Applications (1)

Application Number Title Priority Date Filing Date
HUE10009976A HUE027218T2 (hu) 2003-09-12 2004-09-09 Eljárások IGF-1 (Inzulinszerû növekedési faktor 1) hiány kezeléséhez

Country Status (18)

Country Link
US (3) US7258864B2 (hu)
EP (2) EP1667521B1 (hu)
JP (1) JP4738337B2 (hu)
CN (2) CN1870893A (hu)
AT (1) ATE536186T1 (hu)
AU (1) AU2004291833B2 (hu)
CA (1) CA2538342C (hu)
DK (1) DK2274978T3 (hu)
ES (2) ES2541673T3 (hu)
HU (1) HUE027218T2 (hu)
IL (1) IL174209A (hu)
MA (1) MA28091A1 (hu)
NZ (1) NZ545940A (hu)
PL (1) PL2274978T3 (hu)
PT (1) PT2274978E (hu)
TN (1) TNSN06082A1 (hu)
WO (1) WO2005049792A2 (hu)
ZA (1) ZA200602183B (hu)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ545940A (en) * 2003-09-12 2009-12-24 Tercica Inc Methods for treatment of insulin-like growth factor-1 (IGF-1) deficiency
US8158582B2 (en) * 2005-06-02 2012-04-17 Tercica, Inc. Methods for treatment of insulin-like growth factor-1 deficiency
BRPI0812768A2 (pt) * 2007-06-08 2014-12-02 Massachusetts Inst Technology Igf para o tratamento de síndrome de rett e transtornos sinápticos.
US20090177142A1 (en) 2008-01-09 2009-07-09 Smiths Medical Md, Inc Insulin pump with add-on modules
US8986253B2 (en) 2008-01-25 2015-03-24 Tandem Diabetes Care, Inc. Two chamber pumps and related methods
US8408421B2 (en) 2008-09-16 2013-04-02 Tandem Diabetes Care, Inc. Flow regulating stopcocks and related methods
US8650937B2 (en) 2008-09-19 2014-02-18 Tandem Diabetes Care, Inc. Solute concentration measurement device and related methods
CA2643529C (en) * 2008-11-06 2019-05-21 Kenneth W. Adams Method and composition for enhancement of male erectile function
US9250106B2 (en) 2009-02-27 2016-02-02 Tandem Diabetes Care, Inc. Methods and devices for determination of flow reservoir volume
CA2753214C (en) 2009-02-27 2017-07-25 Tandem Diabetes Care, Inc. Methods and devices for determination of flow reservoir volume
WO2011011071A2 (en) * 2009-07-22 2011-01-27 Ipsen Pharma S.A.S. Analogues of insulin-like growth factor-1 (igf-1)
KR101417872B1 (ko) 2009-07-22 2014-07-09 입센 파마 에스.에이.에스 59번 위치에 아미노산 치환을 포함하는 인슐린 유사 성장 인자-1(ｉｇｆ-1)의 유사체
EP2724739B1 (en) 2009-07-30 2015-07-01 Tandem Diabetes Care, Inc. Portable infusion pump system
WO2011150228A1 (en) * 2010-05-26 2011-12-01 The Children's Hospital Of Philadelphia Research Institute Compositions and methods for the diagnosis and treatment of primary insulin-like growth factor deficiency (pigfd) and idiopathic short stature (iss)
US20130302909A1 (en) * 2011-01-14 2013-11-14 Theratechnologies Inc. Assessment of igf-1 levels in hiv-infected subjects and uses thereof
US9180242B2 (en) 2012-05-17 2015-11-10 Tandem Diabetes Care, Inc. Methods and devices for multiple fluid transfer
US9555186B2 (en) 2012-06-05 2017-01-31 Tandem Diabetes Care, Inc. Infusion pump system with disposable cartridge having pressure venting and pressure feedback
US10201656B2 (en) 2013-03-13 2019-02-12 Tandem Diabetes Care, Inc. Simplified insulin pump for type II diabetics
US9173998B2 (en) 2013-03-14 2015-11-03 Tandem Diabetes Care, Inc. System and method for detecting occlusions in an infusion pump
US9492608B2 (en) 2013-03-15 2016-11-15 Tandem Diabetes Care, Inc. Method and device utilizing insulin delivery protocols
WO2016100528A1 (en) * 2014-12-16 2016-06-23 Puretein Bioscience Llc. Methods for increasing serum igf-1 in an animal
WO2019075404A2 (en) * 2017-10-13 2019-04-18 The Metrohealth System IGF-1 (INSULIN GROWTH FACTOR) AS A THERAPY FOR CARDIAC ARRHYTHMIAS
US10288629B1 (en) * 2017-12-19 2019-05-14 Aeterna Zentaris, Inc. Method of assessing growth hormone deficiency in humans by a macimorelin containing composition
KR102245539B1 (ko) 2018-02-12 2021-04-29 주식회사 지앤피바이오사이언스 코어-쉘 구조의 마이크로 입자를 유효성분으로 포함하는 성장인자 유전자 발현 증가용 조성물
EP3776801A4 (en) 2018-04-10 2021-12-22 Tandem Diabetes Care, Inc. SYSTEM AND METHOD FOR CHARGING BY INDUCTION A MEDICAL DEVICE

Family Cites Families (59)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3773919A (en) 1969-10-23 1973-11-20 Du Pont Polylactide-drug mixtures
US4411890A (en) 1981-04-14 1983-10-25 Beckman Instruments, Inc. Synthetic peptides having pituitary growth hormone releasing activity
US4263428A (en) 1978-03-24 1981-04-21 The Regents Of The University Of California Bis-anthracycline nucleic acid function inhibitors and improved method for administering the same
ATE12348T1 (de) 1980-11-10 1985-04-15 Gersonde Klaus Prof Dr Verfahren zur herstellung von lipid-vesikeln durch ultraschallbehandlung, anwendung des verfahrens und vorrichtung zur durchfuehrung des verfahrens.
IE52535B1 (en) 1981-02-16 1987-12-09 Ici Plc Continuous release pharmaceutical compositions
US4485045A (en) 1981-07-06 1984-11-27 Research Corporation Synthetic phosphatidyl cholines useful in forming liposomes
JPS58118008A (ja) 1982-01-06 1983-07-13 Nec Corp デ−タ処理装置
EP0088046B1 (de) 1982-02-17 1987-12-09 Ciba-Geigy Ag Lipide in wässriger Phase
DE3218121A1 (de) 1982-05-14 1983-11-17 Leskovar, Peter, Dr.-Ing., 8000 München Arzneimittel zur tumorbehandlung
EP0102324A3 (de) 1982-07-29 1984-11-07 Ciba-Geigy Ag Lipide und Tenside in wässriger Phase
ATE220101T1 (de) 1983-04-25 2002-07-15 Chiron Corp Hybrid-dns-synthesis von reifen insulinähnlichen wachstumsfaktoren
IL71991A (en) 1983-06-06 1994-05-30 Genentech Inc Preparation of human FGI and FGE in their processed form through recombinant AND tranology in prokaryotes
US4544545A (en) 1983-06-20 1985-10-01 Trustees University Of Massachusetts Liposomes containing modified cholesterol for organ targeting
HUT35524A (en) 1983-08-02 1985-07-29 Hoechst Ag Process for preparing pharmaceutical compositions containing regulatory /regulative/ peptides providing for the retarded release of the active substance
DE3486459D1 (de) 1983-09-26 1997-12-11 Udo Dr Med Ehrenfeld Mittel und Erzeugnis für die Diagnose und Therapie von Tumoren sowie zur Behandlung von Schwächen der zelligen und humoralen Immunabwehr
DE3474511D1 (en) 1983-11-01 1988-11-17 Terumo Corp Pharmaceutical composition containing urokinase
US4704355A (en) 1985-03-27 1987-11-03 New Horizons Diagnostics Corporation Assay utilizing ATP encapsulated within liposome particles
AU598205B2 (en) 1985-08-22 1990-06-21 Gropep Pty Ltd Peptide analogues of mammalian insulin-like growth factor-1
SE8505922D0 (sv) 1985-12-13 1985-12-13 Kabigen Ab Construction of an igg binding protein to facilitate downstream processing using protein engineering
WO1988007863A1 (en) 1987-04-06 1988-10-20 Biogrowth, Inc. Human somatomedin carrier protein subunits and process for producing them
ATE109828T1 (de) 1987-04-23 1994-08-15 Monsanto Co Sekretion eines dem insulin ähnlichen wachstumsfaktors in e. coli.
US5057417A (en) 1987-06-12 1991-10-15 Genentech, Inc. Compositions and methods for the synthesis of growth hormone receptor and growth hormone binding protein
US4876242A (en) 1987-09-21 1989-10-24 Merck & Co., Inc. Human insulin-like growth factor analoges with reduced binding to serum carrier proteins and their production in yeast
US5283187A (en) 1987-11-17 1994-02-01 Brown University Research Foundation Cell culture-containing tubular capsule produced by co-extrusion
US4892538A (en) 1987-11-17 1990-01-09 Brown University Research Foundation In vivo delivery of neurotransmitters by implanted, encapsulated cells
US5470828A (en) 1987-12-24 1995-11-28 Gropep Pty. Ltd. Peptide analogs of insulin-like growth factor II
JP2507106B2 (ja) 1987-12-24 1996-06-12 グロペップ プロプライエタリー リミテッド インスリン様成長因子１（ｉｇｆ―１）または因子２（ｉｇｆ―２）の類縁ペプチド
DK131988A (da) 1988-03-11 1989-09-12 Erasmus University Igf-bindingsprotein, dna-struktur, der koder for igf-bindingsproteinet og vektor indeholdende denne dna-struktur
US5258287A (en) 1988-03-22 1993-11-02 Genentech, Inc. DNA encoding and methods of production of insulin-like growth factor binding protein BP53
ATE132164T1 (de) 1988-04-12 1996-01-15 Amgen Boulder Inc Verfahren zur steigerung und zur hemmung der wirkung eines insulinähnlichen wachstumfaktors
GB8826451D0 (en) 1988-11-11 1988-12-14 Sandoz Ltd Improvements in/relating to organic compounds
IL92816A0 (en) 1988-12-22 1990-09-17 Biogrowth Inc Recombinant dna molecules,hosts,processes and human somatomedin carrier protein-like polypeptides
CA2025907A1 (en) 1989-09-21 1991-03-22 Franklin D. Collins Method of transporting compositions across the blood brain barrier
US5681814A (en) 1990-06-07 1997-10-28 Genentech, Inc. Formulated IGF-I Composition
US5126324A (en) 1990-06-07 1992-06-30 Genentech, Inc. Method of enhancing growth in patients using combination therapy
US5210017A (en) 1990-11-19 1993-05-11 Genentech, Inc. Ligand-mediated immunofunctional hormone binding protein assay method
US5593844A (en) 1990-11-19 1997-01-14 Genentech, Inc. Ligand-mediated immunofunctional hormone binding protein assay method
US5198340A (en) 1991-01-17 1993-03-30 Genentech, Inc. Assay for free igf-i, igf-ii, and gh levels in body fluids
US5187151A (en) 1991-02-12 1993-02-16 Genentech, Inc. Use of binding protein with igf-i as an anabolic growth promoting agent
US5206235A (en) 1991-03-20 1993-04-27 Merck & Co., Inc. Benzo-fused lactams that promote the release of growth hormone
EP0597033B1 (en) 1991-08-01 1997-04-09 Genentech, Inc. Igf-1 to improve the neural condition
IL105914A0 (en) 1992-06-04 1993-10-20 Univ California Methods and compositions for in vivo gene therapy
GB9217696D0 (en) 1992-08-20 1992-09-30 Agricultural & Food Res Use of specific binding molecules
SK281963B6 (sk) 1993-12-23 2001-09-11 Novo Nordisk A/S Zlúčeniny ovplyvňujúce uvoľňovanie rastového hormónu, farmaceutické prostriedky s ich obsahom a ich použitie
CA2179598A1 (en) 1993-12-23 1995-06-29 Nils Langeland Johansen Compounds with growth hormone releasing properties
US5646113A (en) * 1994-04-07 1997-07-08 Genentech, Inc. Treatment of partial growth hormone insensitivity syndrome
US6207640B1 (en) * 1994-04-07 2001-03-27 Genentech, Inc. Treatment of partial growth hormone insensitivity syndrome
US5824642A (en) * 1994-04-07 1998-10-20 Genentech, Inc. Treatment of partial growth hormone insensitivity syndrome
US5798337A (en) 1994-11-16 1998-08-25 Genentech, Inc. Low molecular weight peptidomimetic growth hormone secretagogues
SE9501472D0 (sv) 1995-04-21 1995-04-21 Pharmacia Ab Truncated IGF-I
US5622932A (en) 1995-05-05 1997-04-22 Eli Lilly And Company IGF-1 superagonists
US5565428A (en) 1995-05-22 1996-10-15 Genentech, Inc. Method of administration of IGF-I
US5741776A (en) * 1995-05-22 1998-04-21 Genentech, Inc. Method of administration of IGF-I
EP0828758B1 (en) 1995-05-26 2001-08-29 Theratechnologies Inc. Chimeric fatty body-pro-grf analogs with increased biological potency
EP0854884A1 (en) 1996-04-17 1998-07-29 Neurocrine Biosciences, Inc. Ligand inhibitors of insulin-like growth factor binding proteins and methods of use therefor
US6121416A (en) 1997-04-04 2000-09-19 Genentech, Inc. Insulin-like growth factor agonist molecules
US6420518B1 (en) 1997-04-04 2002-07-16 Genetech, Inc. Insulin-like growth factor agonist molecules
ES2329220T3 (es) 1999-01-06 2009-11-24 Genentech, Inc. Variantes mutantes del factor de crecimiento similar a insulina (igf) i.
NZ545940A (en) 2003-09-12 2009-12-24 Tercica Inc Methods for treatment of insulin-like growth factor-1 (IGF-1) deficiency

Also Published As

Publication number Publication date
AU2004291833B2 (en) 2010-08-26
MA28091A1 (fr) 2006-08-01
DK2274978T3 (en) 2015-06-15
US20080058259A1 (en) 2008-03-06
TNSN06082A1 (en) 2007-10-03
ATE536186T1 (de) 2011-12-15
JP4738337B2 (ja) 2011-08-03
ES2541673T3 (es) 2015-07-23
EP1667521A2 (en) 2006-06-14
WO2005049792A2 (en) 2005-06-02
US7258864B2 (en) 2007-08-21
JP2007505140A (ja) 2007-03-08
ZA200602183B (en) 2007-07-25
EP1667521A4 (en) 2008-07-02
US20090270323A1 (en) 2009-10-29
CA2538342A1 (en) 2005-06-02
PT2274978E (pt) 2015-07-09
CA2538342C (en) 2013-01-08
AU2004291833A1 (en) 2005-06-02
EP2274978A1 (en) 2011-01-19
IL174209A0 (en) 2006-08-01
PL2274978T3 (pl) 2015-11-30
IL174209A (en) 2012-12-31
CN102861321A (zh) 2013-01-09
US20050059598A1 (en) 2005-03-17
EP2274978B1 (en) 2015-05-20
CN1870893A (zh) 2006-11-29
EP1667521B1 (en) 2011-12-07
US8133862B2 (en) 2012-03-13
ES2373783T3 (es) 2012-02-08
WO2005049792A3 (en) 2006-02-23
NZ545940A (en) 2009-12-24
US7517530B2 (en) 2009-04-14

Similar Documents

Publication Publication Date Title
US7517530B2 (en) Methods for treatment of insulin-like growth factor-1 (IGF-1) deficiency comprising administration of IGF-1 and growth hormone
US7776820B2 (en) Methods for decreasing risk of complications of prematurity using IGF-I and its analogs
Frystyk et al. Increased levels of circulating free insulin-like growth factors in patients with non-islet cell tumour hypoglycaemia
AU2002239560A1 (en) Determination of risk and treatment of complications of prematurity
EP1791551B1 (en) Method and device for diagnosing and treating insulin-like growth factor deficiency disorders
US8440616B2 (en) Methods for treatment of insulin-like growth factor-1 deficiency
US7833964B2 (en) Methods of reducing visceral fat by increasing levels of insulin-like growth factor-I (IGF-I)